Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Endocrine 2Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 52Thyroid Neoplasms 19Thyroid Cancer, Papillary 16Carcinoma, Neuroendocrine 16Pheochromocytoma 11Adrenocortical Carcinoma 11Thyroid Carcinoma, Anaplastic 10Gastro-enteropancreatic neuroendocrine tumor 10Small Cell Lung Carcinoma 9Paraganglioma 9Multiple Endocrine Neoplasia Type 1 9Pituitary Neoplasms 8Lung Neoplasms 8Adenoma, Islet Cell 8Sarcoma 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Medullary 6Adenocarcinoma, Follicular 6Colorectal Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Merkel Cell 5Carcinoid Tumor 5Somatostatinoma 4Pancreatic Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Cholangiocarcinoma 4Carcinoma, Hepatocellular 4

Interventions

pembrolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Small Cell × Endocrine × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡